Inspire Medical Systems, Inc. (NYSE:INSP) Stock Has Average Target Price of $68.82 According to Analysts

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have been given an average rating of “Hold” by the twenty analysts that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $68.82.

INSP has been the topic of several recent research reports. Barclays started coverage on Inspire Medical Systems in a research note on Tuesday, October 6th. They issued an “underweight” rating and a $65.00 price target on the stock. Mizuho set a $75.00 price objective on Inspire Medical Systems in a research note on Tuesday, October 13th. Weiss Ratings raised Inspire Medical Systems from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Finally, Truist Financial increased their target price on Inspire Medical Systems from $62.00 to $78.00 and gave the stock a “hold” rating in a research note on Wednesday, October 14th.

Inspire Medical Systems Price Performance

NYSE:INSP opened at $68.02 on Monday. The firm has a market capitalization of $1.97 billion, a P/E ratio of 31.36, a PEG ratio of 5.38 and a beta of 0.73. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The company’s 50-day simple moving average is $68.59 and its 200 day simple moving average is $58.94.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same quarter last year, the firm earned $0.45 earnings per share. The business’s revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities research analysts expect that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INSP. EverSource Wealth Advisors LLC increased its holdings in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in shares of Inspire Medical Systems by 450.6% during the third quarter. Sterling Capital Management LLC now owns 914 shares of the company’s stock valued at $63,000 after purchasing an additional 748 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of Inspire Medical Systems by 379.0% during the second quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock valued at $43,000 after buying an additional 758 shares during the last quarter. Pinnacle Wealth Planning Services Inc. boosted its position in shares of Inspire Medical Systems by 19.8% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock valued at $81,000 after buying an additional 194 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Inspire Medical Systems by 68.5% during the third quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock valued at $83,000 after buying an additional 488 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.